Time: 1:00 to 2:00 pm EST
Patients with active multiple myeloma typically have a preceding phase of disease referred to as either monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) (also called asymptomatic myeloma). SMM is a stage between MGUS and active myeloma that is associated with a higher risk of progression to myeloma. Patients with SMM typically have no symptoms or signs of active disease (for example, bone lesions or anemia). For this reason, treatment is only started once the disease has progressed to active myeloma. However, some patients with SMM have greater potential to progress to active myeloma than others, and identifying these individuals could potentially prevent that progression from occurring. Clinical trials are currently looking at whether patients with SMM do better when they receive earlier treatment and what type of treatment is best.
Please join the Multiple Myeloma Research Foundation for a FREE webinar developed to help patients, their families and caregivers understand what it means to be diagnosed with SMM and what can be done for those at highest risk for progression.